Abstract The current Zaire ebolavirus (ZEBOV) epidemic in West Africa reinforces the need for effective vaccines and therapeutics that protect against all species of ebolavirus (EBOV). To achieve this, we characterized the effect of virus infection of macrophages and dendritic cells using the recently discovered Bundibugyo ebolavirus (BEBOV). BEBOV infection of humans and nonhuman primates has a lower case fatality rate, differing clinical presentations, and longer time to death compared to ZEBOV. More importantly, survivors and non-survivors of BEBOV have detectable antibodies against BEBOV, indicating that BEBOV interaction with immune cells may differ from ZEBOV. To better understand BEBOV pathogenicity and determine the effects of BEBOV on macrophages and dendritic cells, we performed growth curves and cell characterization in monocyte-derived dendritic cells and PMA-induced THP-1 macrophage-like cells. Over 96 hours, virus production was measured by virus titer, flow cytometry, and qRT-PCR. During monocyte derived dendritic cell experiments, cell surface markers were characterized over time to determine changes induced by EBOV infection. In all cell types tested, BEBOV grows to a lower viral titer. This may play an important role in the overall pathogenesis of BEBOV. Understanding the systemic immune response to BEBOV will aid in determining the mechanism of decreased pathogenesis and identify antiviral targets to be used in developing broad spectrum EBOV therapeutics.